Naturally occurring IgM antibodies to oxidation-specific epitopes

Advances in Experimental Medicine and Biology

Volumn 750, Issue , 2012, Pages 2-13

  Binder, Christoph J ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; EPITOPE; IMMUNOGLOBULIN M ANTIBODY; NATURAL ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG; AUTOANTIBODY; AUTOANTIGEN; IMMUNOGLOBULIN M;

ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNITY; CELL MEMBRANE; CELL VIABILITY; DISEASE ASSOCIATION; HOMEOSTASIS; HOST RESISTANCE; HUMAN; INNATE IMMUNITY; LIPID PEROXIDATION; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PHYLOGENY; PRIORITY JOURNAL; ANIMAL; ANTIBODY AFFINITY; CARDIOVASCULAR DISEASE; CELL AGING; IMMUNOLOGY; INFLAMMATION; OXIDATION REDUCTION REACTION;

ANIMALS; ANTIBODY AFFINITY; AUTOANTIBODIES; AUTOANTIGENS; CARDIOVASCULAR DISEASES; CELL AGING; EPITOPES; HOMEOSTASIS; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULIN M; INFLAMMATION; LIPID PEROXIDATION; OXIDATION-REDUCTION;

EID: 84866791494     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-3461-0_1     Document Type: Article

References (52)

1. Baumgarth N, Tung JW, Herzenberg LA. Inherent specificities in natural antibodies: A key to immune defense against pathogen invasion. Springer Semin Immunopathol 2005; 26:347-62. PMID:15633017 doi:10.1007/s00281-004-0182-2 (Pubitemid 40468889)
2. Baumgarth N. The double life of a B-1 cell: Self-reactivity selects for protective effector functions. Nat Rev Immunol 2011; 11:34-46. PMID:21151033 doi:10.1038/nri2901
3. Boes M. Role of natural and immune IgM antibodies in immune responses. Mol Immunol 2000; 37:1141-9. PMID:11451419 doi:10.1016/S0161-5890(01)00025-6
4. Bendelac A, Bonneville M, Kearney JF. Autoreactivity by design: Innate B and T lymphocytes. Nat Rev Immunol 2001; 1:177-86. PMID:11905826 doi:10.1038/35105052 (Pubitemid 33741955)
5. Lutz HU, Binder CJ, Kaveri S. Naturally occurring auto-antibodies in homeostasis and disease. Trends Immunol 2009; 30:43-51. PMID:19058756 doi:10.1016/j.it.2008.10.002
6. Boes M, Schmidt T, Linkemann K et al. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci USA 2000; 97:1184-9. PMID:10655505 doi:10.1073/pnas.97.3.1184 (Pubitemid 30080833)
7. Chen GY, Nunez G. Sterile inflammation: Sensing and reacting to damage. Nat Rev Immunol 2010; 10:826-37. PMID:21088683 doi:10.1038/nri2873
8. Miller YI, Choi SH, Wiesner P et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 2011; 108:235-48. PMID:21252151 doi:10.1161/CIRCRESAHA.110.223875
9. Chou MY, Hartvigsen K, Hansen LF et al. Oxidation-specific epitopes are important targets of innate immunity. J Intern Med 2008; 263:479-88. PMID:18410591 doi:10.1111/j.1365-2796.2008.01968.x (Pubitemid 351533561)
10. Chang MK, Bergmark C, Laurila A et al. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: Evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci USA 1999; 96:6353-8. PMID:10339591 doi:10.1073/pnas.96.11.6353 (Pubitemid 29256669)
11. Chang MK, Binder CJ, Miller YI et al. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med 2004; 200:1359-70. PMID:15583011 doi:10.1084/jem.20031763 (Pubitemid 39657284)
12. Binder CJ. Natural IgM antibodies against oxidation-specific epitopes. J Clin Immunol 2010; 30(Suppl 1):S56-60. PMID:20387104 doi:10.1007/s10875-010- 9396-3
13. Witztum JL, Steinbrecher UP, Kesaniemi YA et al. Autoantibodies to glucosylated proteins in the plasma of patients with diabetes mellitus. Proc Natl Acad Sci USA 1984; 81:3204-8. PMID:6587346 doi:10.1073/ pnas.81.10.3204 (Pubitemid 14110707)
14. Steinbrecher UP, Fisher M, Witztum JL et al. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. J Lipid Res 1984; 25:1109-16. PMID:6439810 (Pubitemid 15207094)
15. Palinski W, Rosenfeld ME, Yla-Herttuala S et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989; 86:1372-6. PMID:2465552 doi:10.1073/pnas.86.4.1372 (Pubitemid 19061548)
16. Palinski W, Yla-Herttuala S, Rosenfeld ME et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990; 10:325-35. PMID:1693068 (Pubitemid 20178661)
17. Hörkko S, Binder CJ, Shaw PX et al. Immunological responses to oxidized LDL. Free Radic Biol Med 2000; 28:1771-9. PMID:10946219 doi:10.1016/S0891-5849(00)00333-6 (Pubitemid 30628664)
18. Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30:2311-6. PMID:21084697 doi:10.1161/ATVBAHA.108.179697
19. Bochkov VN, Oskolkova OV, Birukov KG et al. Generation and biological activities of oxidized phospholipids. Antioxid Redox Signal 2010; 12:1009-59. PMID:19686040 doi:10.1089/ars.2009.2597
20. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991; 11:81-128. PMID:1937131 doi:10.1016/0891-584 9(91)90192-6
21. Palinski W, Ord VA, Plump AS et al. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 1994; 14:605-16. PMID:7511933 doi:10.1161/01. ATV.14.4.605
22. Palinski W, Tangirala RK, Miller E et al. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15:1569-76. PMID:7583529 doi:10.1161/01.ATV.15.10.1569
23. Chou MY, Fogelstrand L, Hartvigsen K et al. Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 2009; 119:1335-49. PMID:19363291 doi:10.1172/ JCI36800
24. Palinski W, Horkko S, Miller E et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 1996; 98:800-14. PMID:8698873 doi:10.1172/JCI118853 (Pubitemid 26349186)
25. Hörkko S, Bird DA, Miller E et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 1999; 103:117-28. PMID:9884341 doi:10.1172/JCI4533 (Pubitemid 29031170)
26. Shaw PX, Horkko S, Chang MK et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000; 105:1731-40. PMID:10862788 doi:10.1172/JCI8472 (Pubitemid 30421754)
27. Claflin JL, Cubberley M. Clonal nature of the immune response to phosphocholine. VII. Evidence throughout inbred mice for molecular similarities among antibodies bearing the T15 idiotype. J Immunol 1980; 125:551-8. PMID:7391569 (Pubitemid 10045625)
28. Briles DE, Forman C, Hudak S et al. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med 1982; 156:1177-85. PMID:7153709 doi:10.1084/ jem.156.4.1177 (Pubitemid 12036279)
29. Binder CJ, Shaw PX, Chang MK et al. The role of natural antibodies in atherogenesis. J Lipid Res 2005; 46:1353-63. PMID:15897601 doi:10.1194/jlr. R500005-JLR200 (Pubitemid 43109798)
30. Tuominen A, Miller YI, Hansen LF et al. A natural antibody to oxidized cardiolipin binds to oxidized low-density lipoprotein, apoptotic cells, and atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2006; 26:2096-102. PMID:16794225 doi:10.1161/01.ATV.0000233333.07991.4a (Pubitemid 44253794)
31. Merbl Y, Zucker-Toledano M, Quintana FJ et al. Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics. J Clin Invest 2007; 117:712-8. PMID:17332892 doi:10.1172/JCI29943 (Pubitemid 46348529)
32. Notkins AL. Polyreactivity of antibody molecules. Trends Immunol 2004; 25:174-9. PMID:15039043 doi:10.1016/j.it.2004.02.004 (Pubitemid 38368164)
33. Ogden CA, Kowalewski R, Peng Y et al. IgM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity 2005; 38:259-64. PMID:16206508 doi:10.1080/08916930500124452 (Pubitemid 40974955)
34. Chen Y, Park YB, Patel E et al. IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells. J Immunol 2009; 182:6031-43. PMID:19414754 doi:10.4049/jimmunol.0804191
35. Huber J, Vales A, Mitulovic G et al. Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler Thromb Vasc Biol 2002; 22:101-7. PMID:11788468 doi:10.1161/hq0102.101525 (Pubitemid 34076239)
36. Imai Y, Kuba K, Neely GG et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008; 133:235-49. PMID:18423196 doi:10.1016/j.cell.2008.02.043 (Pubitemid 351512299)
37. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-95. PMID:15843671 doi:10.1056/NEJMra043430 (Pubitemid 40530235)
38. Binder CJ, Chang MK, Shaw PX et al. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8:1218-26. PMID:12411948 doi:10.1038/nm1102-1218 (Pubitemid 35373552)
39. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12:204-12. PMID:21321594 doi:10.1038/ni.2001
40. Lewis MJ, Malik TH, Ehrenstein MR et al. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009; 120:417-26. PMID:19620499 doi:10.1161/CIRCULATIONAHA.109.868158
41. Binder CJ, Horkko S, Dewan A et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: Molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003; 9:736-43. PMID:12740573 doi:10.1038/nm876 (Pubitemid 36749223)
42. Berland R, Wortis HH. Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 2002; 20:253-300. PMID:11861604 doi:10.1146/annurev.immunol.20.100301.064833 (Pubitemid 34293426)
43. Faria-Neto JR, Chyu KY, Li X et al. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 2006; 189:83-90. PMID:16386745 doi:10.1016/j.atherosclerosis.2005.11.033 (Pubitemid 44468069)
44. Thorp E, Cui D, Schrijvers DM et al. Mertk receptor mutation reduces efferocytosis efficiency and promotes Thromb Vasc Biol 2008; 28:1421-8. PMID:18451332 doi:10.1161/ATVBAHA.108.167197
45. Reardon CA, Miller ER, Blachowicz L et al. Autoantibodies to OxLDL fail to alter the clearance of injected OxLDL in apolipoprotein E-deficient mice. J Lipid Res 2004; 45:1347-54. PMID:15102879 doi:10.1194/ jlr.M400075-JLR200 (Pubitemid 38802638)
46. Salonen JT, Yla-Herttuala S, Yamamoto R et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339:883-7. PMID:1348295 doi:10.1016/0140-6736(92)90926-T
47. Hulthe J. Antibodies to oxidized LDL in atherosclerosis development-clinical and animal studies. Clin Chim Acta 2004; 348:1-8. PMID:15369729 doi:10.1016/j.cccn.2004.05.021 (Pubitemid 39208994)
48. Karvonen J, Paivansalo M, Kesaniemi YA et al. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 2003; 108:2107-12. PMID:14530200 doi:10.1161/01.CIR.0000092891.55157.A7 (Pubitemid 37337587)
49. Tsimikas S, Brilakis ES, Lennon RJ et al. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res 2007; 48:425-33. PMID:17093289 doi:10.1194/jlr.M600361-JLR200 (Pubitemid 46220609)
50. Sjöberg BG, Su J, Dahlbom I et al. Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. Atherosclerosis 2009; 203:528-32. PMID:18809177 doi:10.1016/j. atherosclerosis.2008.07.009
51. Anania C, Gustafsson T, Hua X et al. Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus. Arthritis Res Ther 2010; 12:R214. PMID:21092251 doi:10.1186/ar3193
52. Su J, Georgiades A, Wu R et al. Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 2006; 188:160-6. PMID:16307748 doi:10.1016/j.atherosclerosis.2005.10.017 (Pubitemid 44160704)